Medivation, Inc. 10,005,000 Shares* Common Stock ($0.01 par value per share) Underwriting AgreementMedivation, Inc. • October 6th, 2005 • Pharmaceutical preparations • New York
Medivation, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to you (collectively, the “Underwriters”) an aggregate of 8,700,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,305,000 additional shares (the “Optional Shares”) of common stock of the Company, $0.01 par value per share (“Common Stock”). The Firm Shares and the Optional Shares which the Underwriters elect to purchase pursuant to Section 3 hereof are herein collectively called the “Shares.”
EXCLUSIVE LICENSE AGREEMENT Between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA And MEDIVATION, INC. and MEDIVATION PROSTATE THERAPEUTICS, INC. (UC Case No. 2004-129) and Novel Prostate Cancer Drugs” (UC Case No. 2005-438)License Agreement • October 6th, 2005 • Medivation, Inc. • Pharmaceutical preparations • California
This Agreement is made and is effective this 12th day of August 2005, (the “Effective Date”) between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its corporate offices located at 1111 Franklin Street, Oakland, California 94607-5200, acting through its offices located at 10920 Wilshire Blvd, Suite 1200, Los Angeles, California 90024-1406, and MEDIVATION, INC. (“Medivation”), a Delaware corporation, and MEDIVATION PROSTATE THERAPEUTICS, INC. (“MPT”) (Medivation and MPT together “Licensee”), a Delaware corporation and wholly-owned subsidiary of Medivation, each having a principal place of business at 501 Second Street, Suite 211, San Francisco, CA 94107.
